Biotech Stocks' Dark Winter Is Over. What That Means For Investors.

Group 1: Biotech Industry Recovery - The biotech sector is experiencing a resurgence, with stock prices reaching levels not seen since late 2021, driven by significant takeover valuations and innovations in obesity and cancer treatments [3] - Experts have long predicted a biotech comeback, which appears to be materializing as shares have climbed following a peak in February 2021 [3] Group 2: Eli Lilly's Acquisition - Eli Lilly has confirmed its plan to acquire Ventyx Biosciences for $1.2 billion, indicating a strategic move to enhance its portfolio in the biotech space [6] - The acquisition aligns with Eli Lilly's focus on expanding its presence in the weight-loss medication market, despite currently lagging behind competitors [8]